Ferrritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population. The D.E.S.I.R. Study: Ferritin, transferin, the metabolic syndrome by Vari, Istvan, et al.
Ferrritin and transferrin are associated with metabolic
syndrome abnormalities and their change over time in a
general population. The D.E.S.I.R. Study
Istvan Vari, Beverley Balkau, Adrien Kettaneh, Philippe Andre´, Jean Tichet,
Fre´de´ric Fumeron, Emile Caces, Michel Marre, Bernard Granchamp, Pierre
Ducimetie`re
To cite this version:
Istvan Vari, Beverley Balkau, Adrien Kettaneh, Philippe Andre´, Jean Tichet, et al.. Fer-
rritin and transferrin are associated with metabolic syndrome abnormalities and their change
over time in a general population. The D.E.S.I.R. Study: Ferritin, transferin, the metabolic
syndrome. Diabetes Care, American Diabetes Association, 2007, 30 (7), pp.1795-1801.
<10.2337/dc06-2312>. <inserm-00138604>
HAL Id: inserm-00138604
http://www.hal.inserm.fr/inserm-00138604
Submitted on 11 Apr 2007
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

   1/23/ 
Ferrritin and transferrin are associated with metabolic syndrome 
abnormalities and their change over time in a general population.  
The D.E.S.I.R. Study 
ISTVAN S VARI, BSC1,2,3  
BEVERLEY BALKAU, PHD1,2 
ADRIAN KETTANEH, MD1,2 
PHILIPPE ANDRE, MD1,2 
JEAN TICHET, MD4 
FREDERIC FUMERON, PHD5 
EMILE CACES, PHARMD4 
MICHEL MARRE, MD,PHD5,6 
BERNARD GRANDCHAMP, MD,PHD7,8 
PIERRE DUCIMETIERE, PHD1,2 
THE D.E.S.I.R. STUDY GROUP4 
From  
1INSERM Unité 780-IFR69, Epidemiological and Biostatistical Research, Villejuif, France 
2Univ Paris Sud, Villejuif, France  
3Ecoles des Hautes Etudes en Sciences Sociales, Paris, France 
4IRSA Institut inter-Régionale pour la Santé, La Riche, France 
5INSERM Unité 695, Genetic Determinants for Type 2 Diabetes and its Vascular 
Complications, Univ Paris 7, Xavier Bichat Medical School, Paris, France  
6Department of Endocrinology, Diabetology, Nutrition and Metabolic Diseases, Xavier Bichat 
Hospital, Paris, France 
7INSERM UMR 773, Denis Diderot Medical School, Université Paris 7, Paris, France 
8Sevice de Biochimie hormonale et Génétique, AP-HP, Xavier Bichat Hospital, Paris, France 
 
 
Short title: Ferritin, transferrin, the metabolic syndrome 
Number of words: abstract: 244, text: 3026 words; 3 tables, 1 figure 
 
Corresponding author: 
Beverley Balkau 
INSERM U780 
Villejuif 94807, France 
Telephone:33145595161, FAX:33147269454 
e-mail balkau@vjf.inserm.fr 
H
AL author m
anuscript    inserm
-00138604, version 1
HAL author manuscript
Diabetes Care 2007; 0
This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes (http://diabetes.diabetesjournals.org). 
The American Diabetes Association (ADA), publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript
or any version derived from it by third parties. The definitive publisher-authenticated version is available online at 10.2337/dc06-2312.
H
AL author m
anuscript    inserm
-00138604, version 1
07/2007; 30(7): 1795-1801
   2/23/ 
OBJECTIVE—To study cross-sectional and longitudinal relations between iron stocks 
(ferritin) and the iron transport protein (transferrin) with the metabolic syndrome and its 
abnormalities.  
METHODS—469 men, 278 pre- and 197 post-menopausal women from the French 
D.E.S.I.R. cohort, aged 30-65 years, were followed over six years.  
RESULTS—Higher concentrations of both ferritin and transferrin were associated with the 
IDF, and NCEP-ATP III original and revised metabolic syndromes at baseline: for the IDF 
metabolic syndrome the standardized, age-adjusted odds ratios (95% CI) for log(ferritin) 
were: 1.49 (1.14-1.94) for men, 2.10 (1.27-3.48) for pre-menopausal women, 1.80 (1.21-2.68) 
for post-menopausal women; for transferrin they were respectively: 1.94 (1.53-2.47), 2.22 
(1.32-3.75), 2.14 (1.47-3.10). After 6-years of follow-up, the change in the presence of the 
metabolic syndrome was associated with higher baseline log(ferritin) in all three groups: 
1.46 (1.13-1.89), 1.28 (0.85-1.94), 1.62 (1.10-2.38), and transferrin: 1.41 (1.10-1.81), 
1.63 (1.05-2.52), 1.51 (1.02-2.22). Among syndrome components, hypertriglyceridemia at 6 
years was the component most strongly associated with baseline ferritin and transferrin. The 
odds of an incident IDF-defined metabolic syndrome after 6 years, was more than four-fold 
higher when ferritin and transferrin were both above the group-specific top tertile, in 
comparison with participants with both parameters below these thresholds. 
CONCLUSIONS—This is the first prospective study associating ferritin and transferrin with 
the metabolic syndrome and its components. When both markers of the iron metabolism are 
elevated, the incidence of the metabolic syndrome is increased in men and both pre- and post-
menopausal women. 
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Abreviations ALT: alanine aminotransferase; CI: confidence interval; CRP: C-reactive 
protein; D.E.S.I.R: Data from an Epidemiological Study on the Insulin Resistance syndrome; 
IDF: International Diabetes Federation; GGT: gamma glutamyl transferase; NCEP-ATP III: 
National Cholesterol Education Program Expert Panel on Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults - Adult Treatment Panel III; OR: odds ratio; 
SD: standard deviation  
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Sullivan formulated in 1981, hypotheses that attributed the sex difference in heart disease risk 
to differences in iron stores (1). Hereditary haemochromatosis, a disorder leading to a chronic 
iron overload syndrome, has been associated with cardiovascular disease and incident 
diabetes (2, 3). Further, in hypercholesterolemic rabbits, iron deposits in atherosclerotic 
lesions occurred secondary to iron overload (4). Some, but not all prospective studies have 
shown that moderately high levels of body iron stores are a risk factor for cardiovascular 
disease, including atherosclerosis (5-9), although a meta-analysis of 12 prospective studies 
concluded that there was no evidence for a strong relation between iron status and coronary 
heart disease (9). Only one of three studies has found blood donation to be cardio-
protective (10-12). 
The implication of iron overload in diabetes was evoked by a small case control study 
in Finnish men (13) and confirmed in two population studies, one of which was prospective 
and showed relations between iron stores and diabetes (14,15). Further, high ferritin levels 
have been associated with the metabolic syndrome and measures of insulin resistance (16-21). 
A syndrome of liver iron overload was proposed by Moirand et al. (22), following an 
observation that there was a higher prevalence of metabolic disorders among patients with 
high ferritin, normal transferrin saturation, normal transferrin but without genetic 
haemochromatosis than among patients with genetic haemochromatosis; both groups had 
similar ferritin levels. The liver iron overload syndrome shares features with the metabolic or 
insulin resistance syndrome. The mechanisms of such an association have not been identified 
and it has been hypothesized that the hyperinsulinemia of the metabolic syndrome could be 
related to an accumulation of iron in the liver (23).  
While ferritin is an indicator of cellular iron stores in healthy subjects, it provides little 
information on iron turn-over in the body. Transferrin is a “shuttle protein” (24), mainly 
synthesized in the liver and its main principal role is to transport ionic iron to the liver, spleen 
and bone marrow (25). Transferrin levels rise with iron deficiency and fall with iron stores.  
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Ferritin and transferrin have been shown to independently predict hyperglycemia in a 
three year follow up of our French cohort: Data for an Epidemiological Study on the Insulin 
Resistance Syndrome (D.E.S.I.R.) (26). We investigate, in the same cohort, over a 6-year 
follow-up period, the relations between these two iron metabolism markers and the metabolic 
syndrome and its constituent abnormalities.  
 
RESEARCH, DESIGN AND METHODS 
Study population 
A total of 5212 men and women, aged 30-65 years, participated in the cohort study: 
D.E.S.I.R. (Data from an Epidemiological Study on the Insulin Resistance Syndrome), a 
longitudinal study that aims to clarify the development of the insulin resistance 
syndrome (27). Participants were recruited in ten Health Examination Centers from volunteers 
insured by the French Social Security system, which offers periodic health examinations free 
of charge. The protocol was approved by the ethics committee of Bicêtre Hospital and 
participants signed an informed consent. 
 Ferritin, transferrin and C-reactive protein (CRP) were measured at baseline in 650 
men and 650 women, randomly selected from among individuals examined at three years. We 
excluded participants with a baseline CRP >10mg/l (43 individuals), because inflammation 
may increase serum ferritin and those with “very low” ferritin, which might be due to anemia: 
<16µg/l in men, <15µg/l in women (63 individuals), and “very high” ferritin, which might be 
due to haemochromatosis: >400µg/l in men and >300µg/l in women (90 individuals) (28-31). 
Analyses are of participants with measures at baseline and at the 6-year follow-up of fasting 
glucose, insulin, triglycerides, HDL-cholesterol, CRP, systolic and diastolic blood pressures 
and waist circumference. The population studied included 469 men and 475 women. 
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Measures 
Blood pressure was taken in a supine position after 5 minutes of rest and waist circumference 
(the smallest circumference between the lower rib and the iliac crests), weight and height 
were measured in lightly clad participants, and the BMI calculated. As part of the clinical 
examination, the physicians noted the menopausal status of the women, after discussion with 
them; hormone levels were not measured. Alcohol intake was determined from a self-
questionnaire where questions on wine, beer, cider, and spirits were asked; the number of 
grams of alcohol per day was then calculated. Drug treatment for hypertension, dyslipidemia 
and diabetes was coded from information provided on this questionnaire  
 All biochemical measurements were from one of four health centre examination 
laboratories at IRSA, Blois, Chartres or Orleans. Total cholesterol, HDL-cholesterol, 
triglycerides, alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) were 
assayed by a DAX 24 (Bayer Diagnostics, Puteaux, France) or a KONE (Evry, France). 
Fasting plasma glucose was measured by the glucose-oxidase method, using a Technicon 
RA100 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta (Konelab, Evry, 
France). ALT and GGT were assayed by enzymatic methods, using a Technicon DAX24 
automatic analyzer (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta (Konelab, 
Evry, France).  Inter-laboratory variability was assessed monthly on normal and pathological 
values for each biologic variable, the coefficients of variation for laboratories were lower than 
6% over the inclusion period. Insulin was centrally assayed on serum by a specific micro-
enzyme immunoassay with an IMX (Abbott, Rungis, France). CRP levels were centrally 
assessed by immunonephelemetric method (Dade Behring Marburg), serum ferritin and 
transferrin used Immunolatex spheres and nephelometry with a BNII nepholemeter (Behring, 
Rueil Malmaison, France). 
 The outcome variables studied are the metabolic syndrome abnormalities defined 
according to the International Diabetes Federation (IDF) criteria (32), and we used three 
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syndrome definitions: IDF, and the National Cholesterol Education Program Expert Panel on 
Detection, Evaluation and Treatment of High Blood Cholesterol in Adults - Adult Treatment 
Panel III (NCEP-ATP III) original and revised syndromes (32-34). The IDF syndrome 
components are: abdominal adiposity, waist circumference ≥94/80cm men/women; 
hyperglycemia, fasting plasma glucose ≥5.6mmol/l or treatment for hyperglycemia; high 
blood pressure, systolic/diastolic blood pressure >130/85mmHg or treatment for hypertension; 
hypo HDL-cholesterolemia, HDL-cholesterol <1.03/1.29mmol/l men/women or treatment for 
lipids; hypertriglyceridemia, triglycerides >1.69mmol/l or treatment for lipids. The IDF 
metabolic syndrome is present if individuals have abdominal adiposity and two or more of the 
other components (32). The NCEP-ATP III syndrome is defined by the presence of three or 
more abnormalities: abdominal adiposity, waist circumference >102/88cm men/women; 
hyperglycemia, fasting plasma glucose ≥6.1 mmol/l; high blood pressure, systolic/diastolic 
blood pressure >130/8mmHg; hypo-HDL cholesterolemia, HDL-cholesterol 
<1.03/1.29mmol/l men/women; hypertriglyceridemia, triglycerides >1.69mmol/l (33). The 
revised NCEP-ATP III syndrome includes treatment for glucose, lipids and hypertension in 
the corresponding abnormalities, and hyperglycemia is a fasting plasma glucose ≥5.6mmol/l 
(34). Hyperinsulinemia was defined when the insulin concentration was above the upper 
quartile for each group, and insulin resistance (HOMA2-IR) and β -cell function (HOMA2-
% β), evaluated by the HOMA2 model (35), used quartile cut-points. 
Statistical methods  
Analyses are by gender and for women according to menopausal status. Because of skewed 
distributions, ferritin levels were log-transformed. Characteristics of the studied population 
are described by means (SD), geometric means, percentages and compared between groups by 
Wilcoxon or χ2 tests. Associations between parameters were evaluated by Spearman 
correlation coefficients.  
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Age-adjusted logistic regression models were used to study the presence of the IDF 
defined metabolic syndrome abnormalities, the IDF, NCEP original and revised metabolic 
syndromes, hyperinsulinaemia, insulin resistance and β-cell function according to the two iron 
parameters at baseline: log(ferritin) and transferrin, both studied as continuous variables, at 
inclusion and at the 6-year follow-up; the 6-year models were adjusted for the presence of the 
corresponding abnormality at inclusion, thus the models tested essentially whether the iron 
parameters were associated with the change in syndrome components during the 6 year-
period. To increase the power of our analyses, data from men and women were pooled, and 
the same relations studied, after also adjusting for the three groups. All associations were 
expressed as the odds ratio (OR) for a one standard deviation increase in the baseline 
log(ferritin) and transferrin, using the respective group standard deviations. This enables the 
comparison of the strength of the association for the two iron markers with the various 
outcomes studied. 
The incidence of the IDF defined metabolic syndrome was studied at the 6-year 
follow-up among 371 men, 256 pre- and 150 post-menopausal women without the syndrome 
at entry, for combinations of high and low levels of the iron parameters: the upper one third 
and the lower two-thirds of the sex-specific ferritin and transferrin distributions, with tertiles: 
208, 58, 109 µg/l for ferritin and 2.37, 2.45, 2.42 g/l for transferrin in men, pre- and post-
menopausal women respectively. 
 Analyses used: SAS Version 9.1.3 (SAS Institute Inc. Cary, NC USA). 
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RESULTS—At baseline, the population was middle-aged, men: 47 years, pre-menopausal 
women 41 years, and post-menopausal women 57 years (Table 1). The average ferritin 
concentration in men, 178 µg/l, was nearly two times higher than that in post-menopausal 
women, 92 µg/l, and three-fold higher than in pre-menopausal women. In contrast, mean 
transferrin concentrations were similar in the three groups, 2.3 g/l. 
Ferritin and transferrin were negatively correlated, but this was only statistically 
significant in pre-menopausal women (r = -0.30) (Table 2). CRP was not correlated with 
ferritin, but was correlated with transferrin in both pre and post-menopausal women. Waist 
circumference, triglycerides, insulin and HOMA-IR were significantly correlated with ferritin 
and with transferrin in all three groups. Higher values of hepatic markers, ALT and GGT were 
significantly correlated with both ferritin and transferrin, (exceptions were transferrin with 
ALT in pre-menopausal women and with GGT in post-menopausal women).  
In men and in post-menopausal women the syndrome was more frequent than in pre-
menopausal women, for the IDF syndrome: 21%, 24% and 8% respectively (Table 3). 
However, the standardized odds ratios associated with the syndrome were not dissimilar 
between these three groups: for the IDF syndrome at baseline for log(ferritin) 1.49, 1.80, 2.10, 
respectively, and for transferrin 1.94, 2.14, 2.22 and all were statistically significant. At the 
six year follow-up, the corresponding odds ratios were lower: 1.46, 1.62, 1.28 for log(ferritin) 
and 1.41, 1.51, 1.63, for transferrin, respectively. These relations were statistically significant 
(p < 0.05), with the exception of ferritin in pre-menopausal women.  
Both baseline ferritin and transferrin concentrations were associated with many of the 
metabolic syndrome abnormalities, with hyperinsulinemia, HOMA-IR and HOMA-%β, both 
cross-sectionally and after 6 years of follow-up, although these relations were not always 
statistically significant (Table 3). The most consistent relations were with hyper-
triglyceridemia, hyperinsulinemia and the metabolic syndrome by any definition, with slightly 
stronger relations at baseline than at follow-up. These relations remained after further 
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adjustment on alcohol intake, CRP, ALT and GGT (data not shown). There were fewer 
significant relations in women, partly due to the fact that numbers in both the pre- and pos-
menopausal groups were smaller.  
Concentrations of both ferritin and transferrin above the group-specific higher tertiles, 
were associated with a significantly higher incidence of the IDF-defined syndrome in men and 
post-menopausal women (both p < 0.004), and there was a trend for a higher incidence in pre-
menopausal women (p = 0.08) (Fig. 1). In these younger women there were only 10% who 
had an incident metabolic syndrome, in comparison to 17% in the men and 21% in the post-
menopausal women. In the-pooled data, the odds ratios associated with high values of the iron 
parameters, separately or together, were significantly higher than in the 45% of our population 
with both parameters below the upper tertile. 
 
DISCUSSION— Higher levels of ferritin and transferrin at baseline, were associated with the 
metabolic syndrome anomalies, hyperinsulinemia, high HOMA-IR and low HOMA-%β and 
with an increased prevalence of the metabolic syndromes. They were also associated, over the 
6-year follow-up, with a worsening profile. 
While our cross-sectional results on ferritin are similar to those found in the literature 
(16-21), we have been able to analyze this relation longitudinally and further, to show that 
transferrin is also associated with the metabolic syndrome. In the sub-group of individuals 
with ferritin and transferrin both above the upper tertile, there was a four times higher odds of 
incident IDF-defined metabolic syndrome, in comparison with those with both iron 
parameters below the upper tertile. 
In our previous analysis (26) we studied only two outcomes: fasting insulin and 
glucose concentrations, and we find the same results here, both at baseline and longitudinally; 
in the present analysis with the exclusion criteria for CRP and ferritin the population studied 
is smaller, but the follow-up is longer. In accordance with the results from NHANES (19) but 
H
AL author m
anuscript    inserm
-00138604, version 1
H
AL author m
anuscript    inserm
-00138604, version 1
   11/23/ 
in contrast to Sheu et al. in a Chinese population (18), the ferritin level was found to be 
associated with the metabolic syndrome and hyperinsulinemia in both men and post-
menopausal women and this relationship also held for predicting change over 6 years, 
although with a lower odds ratio. We also found that this association was independent of CRP 
and liver enzymes. 
Our study is limited by the small sample size, particularly in pre- and post-menopausal 
women. Not all individuals had data available at 6 years, but they had similar mean values for 
all parameters, excepting men who had a significantly higher baseline CRP, glucose, insulin, 
triglycerides and a lower HDL-cholesterol, and post-menopausal women who had a higher 
mean triglycerides concentration. Consequently the metabolic syndrome would be more 
frequent in those lost to follow-up and very likely the incidence would also have been higher, 
leading to a lowering of power in the analysis.  
The frequency of the metabolic syndrome increased with both serum transferrin and 
ferritin, cross-sectionally and with change after 6 years, adding credibility to the hypothesis 
that the iron metabolism might participate in the etiology of insulin resistance. Transferrin has 
been shown to be a major determinant of lipolytic activity in adipocytes by a pro-oxidative 
mechanism (36) and thus may be involved in an enhanced free fatty acid metabolism, in the 
development of insulin resistance and its associated abnormalities. Transferrin has also been 
shown to be an insulin agonist and this effect is likely to extend to skeletal muscle (37,38). 
Moreover, an insulin resistance phenotype has been associated with liver iron overload, and it 
is characterized by normal transferrin saturation, normal transferrin and high ferritin, in 
patients without genetic haemochromatosis (22). The consistent association of ferritin and 
transferrin with both hypertriglyceridemia and hyperinsulinemia in the present study are in 
accord with these hypotheses. The mechanism proposed by Ferrannini (23), that 
hyperinsulinemia may be directly responsible for the accumulation of iron in the liver appears 
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to be less in agreement with our findings, that baseline ferritin and transferrin levels were 
predictive of the metabolic syndrome and hyperinsulinemia changes during follow-up.  
Whatever the complex mechanisms, which underlie these associations, the present 
data indicate that not only iron stores but also iron transport is involved in the development of 
the metabolic syndrome and very likely of insulin resistance. Similar analyses should be 
performed in other populations, as they may have important implications for screening and 
prevention of type 2 diabetes and its complications. 
___________________________________________________________________________ 
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Table 1—Baseline characteristics (mean (SD), n (%)) of men and women studied
The D.E.S.I.R. Study. 
 
Women P-values 
Men & 
Women  
Pre- & Post
menopausal 
Women 
  Men 
Pre-
menopausal 
Post-
menopausal 
 
n 469 278 197    
Age (years) 47 (10) 41 (7) 57 (5) 0.3 <0.0001 
Ferritin (µg/l) 178 (90) 56.4(40.8) 91.7(54.3) <0.0001 <0.0001 
     Geometric mean (µg/l) 152 45.9 76.5 <0.0001 <0.000 
Transferrin (g/l) 2.27 (0.30) 2.33 (0.36) 2.30 (0.36) 0.1 0.2 
CRP (mg/l) 1.61 (1.43) 1.75(1.60) 1.88 (1.57) 0.05 0.1 
Waist circumference (cm) 89 (9) 75 (9) 80 (10) <0.0001 <0.0001 
BMI (kg/m²) 25.4 (3.2) 23.3 (3.6) 24.7 (3.7) <0.0001 <0.0001 
Systolic BP (mmHg) 132 (15) 122 (15) 132 (16) <0.0001 <0.0001 
Diastolic BP (mmHg) 82 (10) 76 (10) 79 (9) <0.0001 <0.0001 
Total cholesterol (mmol/l) 5.76 (0.92) 5.42 (0.86) 6.01 (0.97) 0.1 <0.0001 
HDL-cholesterol (mmol/l) 1.50 (0.37) 1.76 (0.42) 1.87 (0.46) <0.0001 0.009 
Triglycerides (mmol/l) 1.18 (0.63) 0.94 (0.53) 0.99 (0.48) <0.0001 0.02 
Plasma glucose (mmol/l) 5.54 (0.60) 5.07 (0.70) 5.26 (1.08) <0.0001 0.004 
Serum insulin (pmol/l) 47.5 (28.2) 42.8 (22.2) 42.3 (21.9) 0.01 0.9 
HOMA2 IR 1.05 (0.63) 0.92 (0.49) 0.93 (0.49) <0.0001  0.8 
HOMA2-%β 78 (29) 87 (31) 81 (25) <0.001 0.009 
Alcohol consumption (g/d) 23 (22) 6.7 (10.3) 8.6 (12.1) <0.0001 0.7 
ALT (U/l) 29.7 (16.7) 17.9 (7.4) 21.7 (9.1) <0.0001 <0.0001 
GGT (U/l) 39.7 (39.5) 20.5 (15.8) 23.0 (15.0) <0.0001 0.007 
Number (%) of participants with medication for 
      hypertension 48 (10.2) 18 (6.5) 36 (18.3) 0.6 <0.0001 
      dyslipidemia 41 (8.7) 4 (1.4) 24 (12.2) 0.09 <0.0001 
      hyperglycemia 7 (1.5) 1 (0.4) 1 (0.5) 0.9 0.9 
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Table 2—Spearman correlation coefficients of baseline characteristics with ferritin and 
transferrin, according to gender and menopausal status. The D.E.S.I.R. study  
 
 
Men 
n=469 
Pre-menopausal women 
n=278 
Post-menopausal women 
n=197 
 Ferritin Transferrin Ferritin Transferrin Ferritin Transferrin 
Ferritin - -0.05 - -0.30*** - -0.05 
Age 0.01 0.03 0.16** -0.13* 0.19** 0.06 
CRP 0.04 0.05 0.05 0.24*** 0.13 0.17* 
Waist  0.21*** 0.21*** 0.15* 0.14* 0.25*** 0.19* 
BMI 0.24*** 0.19*** 0.12* 0.07 0.19** 0.17* 
Systolic BP 0.10* 0.06 0.11 0.08 0.15* -0.00 
Diastolic BP 0.13** 0.16*** 0.08 0.08 0.09 -0.07 
HDL-
cholesterol 
-0.09 -0.02 -0.04 -0.11 -0.15* 0.01 
Triglycerides 0.16*** 0.16*** 0.12* 0.35*** 0.27*** 0.18*  
Glucose 0.14** 0.04 0.25*** -0.08 0.21** 0.20** 
Insulin 0.24*** 0.16** 0.17** 0.19** 0.26*** 0.18** 
HOMA2-IR 0.24*** 0.16*** 0.19** 0.18** 0.27*** 0.19** 
HOMA2-%β 0.17** 0.15*** 0.02 0.24*** 0.11 0.05 
Alcohol  0.06 0.11* 0.15* 0.09 0.11 0.01 
ALT 0.20*** 0.24*** 0.13* 0.01 0.22** 0.20** 
GGT 0.19*** 0.24*** 0.24*** 0.13* 0.27*** 0.11 
* p < 0.05, ** p < 0.01, *** p < 0.001 
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Figure Legend 
Figure—Age-adjusted odds ratios (95% confidence interval) for the 6-year incidence of the IDF-
defined metabolic syndrome according to: A. high ferritin and transferrin levels (both above the 
upper tertiles); B. lower ferritin, high transferrin; C. high ferritin, lower transferrin; D. lower 
ferritin, lower transferrin; high and low levels were defined according to the three groups: men, 
pre-menopausal women, menopausal women. The D.E.S.I.R. Study 
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